Bungari - Tiếng Bulgaria - Изпълнителна агенция по лекарствата

pharmaceutical works jelfa s.a., - Комбинации от кортикостероиди - 0,2 mg/30 mg/g ointment

Bungari - Tiếng Bulgaria - Изпълнителна агенция по лекарствата

Софарма АД - Симпатикомиметична, комбинация искл. кортикостероиди - 30 mg/g + 50 mg/g nasal ointment

Bungari - Tiếng Bulgaria - БАБХ (Българска агенция по безопасност на храните)

ВЕТПРОМ АД - Дексаметазон - инжекционен разтвор - 0, 004 g/ml - говеда, кози, коне, котки, кучета, свине

Liên Minh Châu Âu - Tiếng Bulgaria - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - Артрит, ревматоиден - Имуносупресори - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Liên Minh Châu Âu - Tiếng Bulgaria - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - астма - Лекарства за обструктивна заболявания на дихателните пътища, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Liên Minh Châu Âu - Tiếng Bulgaria - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - астма - Лекарства за обструктивна заболявания на дихателните пътища, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Liên Minh Châu Âu - Tiếng Bulgaria - EMA (European Medicines Agency)

teva b.v. - xinafoate салметерол, флутиказона пропионат - астма - Лекарства за обструктивна заболявания на дихателните пътища, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Liên Minh Châu Âu - Tiếng Bulgaria - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - астма - Лекарства за обструктивна заболявания на дихателните пътища, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Liên Minh Châu Âu - Tiếng Bulgaria - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - астма - Лекарства за обструктивна заболявания на дихателните пътища, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Liên Minh Châu Âu - Tiếng Bulgaria - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - Дерматит, Атопич - Други дерматологични препарати - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.